← back to search

Natalie I. Vokes

The University of Texas MD Anderson Cancer Center · US
🔎 Find collaborators in Oncology · Pulmonary and Respiratory Medicine →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies, and Cancer Genomics and Diagnostics.
h-index
31
citations
8,974
works
350
NIH funding
primary concept
Medicine
email

Recent publications

Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception
Cancer Cell 2025cited by 26position: middledoi
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study
The Lancet Oncology 2025cited by 5position: middledoi
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Nature 2024cited by 145position: middledoi
Ten challenges and opportunities in computational immuno-oncology
Journal for ImmunoTherapy of Cancer 2024cited by 10position: middledoi
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
Nature Genetics 2023cited by 181position: middledoi
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study
The Lancet Digital Health 2023cited by 107position: middledoi
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance
Nature Genetics 2023cited by 85position: middledoi
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Clinical Cancer Research 2023cited by 34position: middledoi
Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
JAMA Oncology 2022cited by 376position: middledoi
Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma
Journal of Thoracic Oncology 2022cited by 150position: firstdoi
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
Cancer Cell 2021cited by 620position: middledoi
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status
Journal of Thoracic Oncology 2021cited by 363position: middledoi
Transcriptional mediators of treatment resistance in lethal prostate cancer
Nature Medicine 2021cited by 191position: middledoi
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma
Nature Communications 2021cited by 163position: middledoi
Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology
Nature Cancer 2021cited by 44position: middledoi
Integrated molecular drivers coordinate biological and clinical states in melanoma
Nature Genetics 2020cited by 50position: middledoi
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
Nature Medicine 2020cited by 12position: middledoi
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
Nature Medicine 2019cited by 1,089position: middledoi
Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non–Small-Cell Lung Cancer
JCO Precision Oncology 2019cited by 120position: firstdoi
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Nature Genetics 2018cited by 693position: middledoi
Tracing Compartmentalized NADPH Metabolism in the Cytosol and Mitochondria of Mammalian Cells
Molecular Cell 2014cited by 583position: middledoi
Reductive glutamine metabolism is a function of the α-ketoglutarate to citrate ratio in cells
Nature Communications 2013cited by 363position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Eliezer M. Van Allen · Harvard University5 papers (2019–2024)Felix Dietlein · Harvard University3 papers (2019–2021)Lynette M. Sholl · Harvard University2 papers (2019–2022)Saud H. AlDubayan · Brigham and Women's Hospital2 papers (2020–2021)Haitham Elmarakeby · Broad Institute2 papers (2019–2021)Matthew G. Vander Heiden · Broad Institute2 papers (2013–2014)Tanya E. Keenan · Massachusetts Institute of Technology2 papers (2020–2021)Pasi A. Jänne · Harvard University2 papers (2019–2022)Jake R. Conway · Broad Institute2 papers (2020–2021)Claire A. Margolis · Massachusetts Institute of Technology2 papers (2019–2020)Mizuki Nishino · Harvard University2 papers (2019–2022)Brendan Reardon · Broad Institute2 papers (2020–2021)Himangi Marathe · Roswell Park Comprehensive Cancer Center1 papers (2024–2024)Rizwan Haq · Harvard University1 papers (2020–2020)Renato Umeton · Broad Institute1 papers (2019–2019)Song Liu · Shandong Academy of Sciences1 papers (2024–2024)Jihye Park · Ewha Womans University1 papers (2021–2021)Qingrong Chen · Center for Cancer Research1 papers (2024–2024)Seth J. Parker · Pacific Centre for Reproductive Medicine1 papers (2014–2014)Lyndsay Harris · Yale Cancer Center1 papers (2024–2024)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Oncology · Pulmonary and Respiratory Medicine →